Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis

Journal of Pathology

Volumn 188, Issue 2, 1999, Pages 180-188

  Kaikita, Koichi ^a   Takeya, Motohiro ^a   Ogawa, Hisao ^a   Suefuji, Hisakazu ^a   Yasue, Hirofumi ^a   Takahashi, Kiyoshi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary atherosclerosis; Macrophage; Thrombogenicity; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

THROMBOPLASTIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THROMBOGENICITY;

AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; FIBRIN; FOAM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; MACROPHAGES; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; THROMBOPLASTIN;

EID: 0033014459     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO;2-Q     Document Type: Article

References (41)

1. Fusler V, Lewis A. Conner Memorial Lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2125-2146.
2. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation 1989; 80: 198-205.
3. Fernández-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
4. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
5. Nemerson Y. The reaction between bovine brain tissue factor and Factors VII and X. Biochemistry 1966; 5: 601-608.
6. Ōsterud B, Rapaport SI. Activation of Factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264.
7. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
8. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
9. Marmur JD, Thiruvikramen SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
10. Moreno PR, Bernardi VH, López-Cuéllar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-3097.
11. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
12. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-771.
13. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997; 17: 2232-2237.
14. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor show that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004.
15. Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546.
16. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
17. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/Factor Vila activity in plasma requires Factor X and an additional plasma component, Blood 1985; 66: 204-212.
18. Hubbard AR, Jennings CA. Inhibition of the tissue factor-Factor VII complex; involvement of Factor Xa and lipoproteins. Thromb Res 1987; 46: 527-537.
19. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the Factor VH-tissue factor complex also inhibits Factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
20. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-949.
21. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
22. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-369.
23. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
24. Kelly PMA, Bliss E, Morton JA, Burns J, McGee J. Monoclonal antibody EBM/11: high cellular specificity for human macrophages. J Clin Pathol 1988; 41: 510-515.
25. Tsukada T, Tippens D, Gordon D, Ross R, Gown AM. HHF35, a muscle-actin-specific monoclonal antibody. Am J Pathol 1987; 126: 51-60.
26. Naiem M, Gerdes J, Abdulaziz Z, et al. The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods 1982; 50: 145-160.
27. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132.
28. Isobe Y, Chen ST, Nakane PK, Brown WR. Studies on translocation of immunoglobulins across intestinal epithelium. I. Improvements in the peroxidase-labeled antibody method for application to study human intestinal mucosa. Acta Histochem Cytochem 1977; 10: 167-171.
29. Greenberg ME. Preparation and analysis of RNA. In: Ausubel FM, Brent R, Kingston RE, et al., eds. Current Protocols in Molecular Biology. New York: Green Publishing Associates and Wiley-Interscience, 1989: 4.2.1-4.2.6.
30. Bajaj MS, Rana SV, Wysoimerski RB, Bajaj SP. Inhibitor of the Factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
31. Ameri A, Kuppuswanmy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-3226.
32. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2055-2062.
33. Bajaj MS, Kuppuswanmy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-8873
34. McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994; 179: 1847-1854.
35. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
36. Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-656.
37. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
38. Kokawa T, Abumiya T. Kimura T, et al. Tissue factor pathway inhibitor activity in human plasma: measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504-510.
39. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-2025.
40. Edwards R, Rickles FR. Macrophage procoagulants. Prog Hemostas Thrombos 1984; 7: 183-209.
41. Gregory SA, Edgington TS. Tissue factor induction in human monocytes: two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J Clin Invest 1985; 76: 2440-2445.